180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.
Company profile
Ticker
ATNF
Exchange
Website
CEO
Jim N. Woody
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
KBL MERGER CORP. IV
SEC CIK
Corporate docs
Subsidiaries
180 Life Corp. • Katexco Callco ULC • CannBioRex Callco ULC • 180 Therapeutics LP • Katexco Purchaseco ULC • CannBioRex Purchaseco ULC • Katexco Pharmaceuticals Corp. • CannBioRex Pharmaceuticals Corp. • CannBioRex Pharma Limited ...
ATNF stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
25 Apr 24
EFFECT
Notice of effectiveness
25 Apr 24
POS AM
Prospectus update (post-effective amendment)
19 Apr 24
POS AM
Prospectus update (post-effective amendment)
19 Apr 24
8-K
Changes in Registrant's Certifying Accountant
19 Apr 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
Other Events
14 Mar 24
8-K
Departure of Directors or Certain Officers
11 Mar 24
8-K
Unregistered Sales of Equity Securities
8 Mar 24
8-K
Unregistered Sales of Equity Securities
1 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 7 |
Closed positions | 5 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 77.79 mm |
Total shares | 4.93 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
KBL Iv Sponsor | 2.22 mm | $5.47 mm |
Bauer Ronald | 1.41 mm | $7.02 mm |
Bridgman Craig | 673.51 k | $3.36 mm |
CNH Partners | 336.51 k | $3.77 mm |
Renaissance Technologies | 120.00 k | $140.00 k |
MSD Partners | 90.00 k | $1.06 mm |
Two Sigma Securities | 22.81 k | $269.00 k |
Vanguard | 15.38 k | $17.99 mm |
BLK Blackrock | 14.65 k | $17.15 mm |
Geode Capital Management | 10.60 k | $12.40 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Dec 23 | Marc Feldmann | Common Stock | Grant | Acquire A | No | No | 0 | 135,377 | 0.00 | 250,874 |
15 Dec 23 | James N. Woody | Common Stock | Buy | Acquire P | No | No | 0.188 | 25,000 | 4.70 k | 66,888 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
5 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
25 Mar 24
12 Health Care Stocks Moving In Friday's Intraday Session
22 Mar 24
180 Life Sciences Regains Full Compliance With Nasdaq Minimum Bid Price Requirement
14 Mar 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
13 Mar 24